Cytek Biosciences Inc
NASDAQ:CTKB
Intrinsic Value
Cytek Biosciences, Inc. is a life sciences technology company engages in the provision of cell analysis tools by leveraging novel technical approaches. [ Read More ]
The intrinsic value of one CTKB stock under the Base Case scenario is 7.48 USD. Compared to the current market price of 5.63 USD, Cytek Biosciences Inc is Undervalued by 25%.
Valuation Backtest
Cytek Biosciences Inc
Run backtest to discover the historical profit from buying and selling CTKB stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Cytek Biosciences Inc
Current Assets | 392.1m |
Cash & Short-Term Investments | 262.4m |
Receivables | 56.1m |
Other Current Assets | 73.5m |
Non-Current Assets | 102.4m |
PP&E | 29.3m |
Intangibles | 39.3m |
Other Non-Current Assets | 33.9m |
Current Liabilities | 56.2m |
Accounts Payable | 3m |
Accrued Liabilities | 24.2m |
Other Current Liabilities | 29m |
Non-Current Liabilities | 45.2m |
Long-Term Debt | 1.6m |
Other Non-Current Liabilities | 43.5m |
Earnings Waterfall
Cytek Biosciences Inc
Revenue
|
193m
USD
|
Cost of Revenue
|
-83.6m
USD
|
Gross Profit
|
109.4m
USD
|
Operating Expenses
|
-137.3m
USD
|
Operating Income
|
-27.8m
USD
|
Other Expenses
|
15.7m
USD
|
Net Income
|
-12.1m
USD
|
Free Cash Flow Analysis
Cytek Biosciences Inc
CTKB Profitability Score
Profitability Due Diligence
Cytek Biosciences Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
Score
Cytek Biosciences Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
CTKB Solvency Score
Solvency Due Diligence
Cytek Biosciences Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Cytek Biosciences Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CTKB Price Targets Summary
Cytek Biosciences Inc
According to Wall Street analysts, the average 1-year price target for CTKB is 10.2 USD with a low forecast of 9.09 USD and a high forecast of 12.6 USD.
Ownership
CTKB Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CTKB Price
Cytek Biosciences Inc
Average Annual Return | -19.93% |
Standard Deviation of Annual Returns | 30.26% |
Max Drawdown | -85% |
Market Capitalization | 735.9m USD |
Shares Outstanding | 130 824 000 |
Percentage of Shares Shorted | 8.65% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Cytek Biosciences, Inc. is a life sciences technology company engages in the provision of cell analysis tools by leveraging novel technical approaches. The company is headquartered in Fremont, California and currently employs 496 full-time employees. The company went IPO on 2021-07-23. The firm offers cell analysis tools by leveraging technical approaches. Its instruments, the Aurora and Northern Lights systems, are the spectrum flow cytometers able to deliver cell analysis by utilizing the spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells Full Spectrum Profiling (FSP). The Company’s FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize a method of light detection and distribution. Its FSP platform includes instruments, reagents, software and services to provide an integrated suite of solutions for its customers. The firm has sold and deployed over 1,000 instruments, primarily comprised of its Aurora and Northern Lights systems to customers around the world, including the pharmaceutical companies, over 150 biopharma companies, academic research centers, and clinical research organizations (CROs).
Contact
IPO
Employees
Officers
The intrinsic value of one CTKB stock under the Base Case scenario is 7.48 USD.
Compared to the current market price of 5.63 USD, Cytek Biosciences Inc is Undervalued by 25%.